Aerobic glycolysis essential for eye development in mammals, study finds

Take­da’s Phase II pro­gram in a rare hered­i­tary dis­ease called metachro­mat­ic leukody­s­tro­phy (MLD) is “like­ly to be dis­con­tin­ued” af­ter fail­ing its pri­ma­ry and sec­ondary end­points,

Ter­re­mo­to Bio­sciences has reeled in $175 mil­lion to cre­ate small mol­e­cules based on work from Prin­cip­ia Bio­phar­ma co-founder Jack Taunton and Glob­al Blood Ther­a­peu­tics co-founder

A toxoid vaccine candidate against Clostridioides difficile failed to reduce the incidence of infection in at-risk adults ages 50 and older, according to results of